Showing results (121-130 of 131) with videos related to
Sort By:
Pageof 14
International Journal of Urology : Official Journal of the Japanese Urological Association|April 24, 2025
The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study)Koshiro Nishimoto, Go Kimura, Tomokazu Sazuka, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Clinical Predictors of Response to Testosterone Replacement Therapy in Boys With Micropenis: A Retrospective Study Focusing on Penile Morphology and Hormonal FactorsJunki Harada, Kensuke Mitsunari, Shota Kakita, et al.International Journal of Clinical Oncology|February 14, 2025
Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatmentKojiro Ohba, Takahiro Osawa, Takahiro Kojima, et al.Japanese Journal of Clinical Oncology|January 22, 2021
External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohortKeita Tamura, Takahiro Osawa, Ario Takeuchi, et al.Cancer Science|September 24, 2025
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With NivolumabTokiyoshi Tanegashima, Masaki Shiota, Shusuke Akamatsu, et al.Cancer Immunology, Immunotherapy : CII|February 2, 2023
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trialMasaki Shiota, Hideaki Miyake, Masayuki Takahashi, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|August 2, 2023
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC studyLeandro Blas, Masaki Shiota, Hideaki Miyake, et al.JCO Clinical Cancer Informatics|April 25, 2025
Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC StudyMasaki Shiota, Shota Nemoto, Ryo Ikegami, et al.Urologic Oncology|October 5, 2023
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairmentKeita Minami, Takahiro Osawa, Takahiro Kojima, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 17, 2024
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC StudyTokiyoshi Tanegashima, Masaki Shiota, Nobuhiro Fujiyama, et al.Pageof 14